CYTEK BIOSCIENCES, INC.

(CTKB)
  Report
Delayed Nasdaq  -  05/26 04:00:01 pm EDT
9.710 USD   +4.86%
05/24Cytek Biosciences Receives CE Marking for cFluor Reagents, TBNK Kit in Europe
MT
05/24Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit
GL
05/16Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cytek Biosciences, Inc.(NasdaqGS:CTKB) added to S&P Global BMI Index

12/20/2021 | 12:00am EDT

Cytek Biosciences, Inc.(NasdaqGS:CTKB) added to S&P Global BMI Index


© S&P Capital IQ 2021
All news about CYTEK BIOSCIENCES, INC.
05/24Cytek Biosciences Receives CE Marking for cFluor Reagents, TBNK Kit in Europe
MT
05/24Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit
GL
05/16Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Ove..
MT
05/12Morgan Stanley Lowers Price Target for Cytek Biosciences to $11 From $18, Maintains Equ..
MT
05/12INSIDER SELL : Cytek Biosciences
MT
05/12Goldman Sachs Lowers Cytek Biosciences Price Target to $12 From $14, Buy Rating Maintai..
MT
05/12CYTEK BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/11Cytek Biosciences Posts Flat Adjusted EPS, Higher Revenue for Q1; Sees 2022 Revenue at ..
MT
05/11Cytek Biosciences Seeks M&A
CI
05/11TRANSCRIPT : Cytek Biosciences, Inc., Q1 2022 Earnings Call, May 11, 2022
CI
More news
Analyst Recommendations on CYTEK BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 242 M - -
Net income 2022 1,98 M - -
Net cash 2022 366 M - -
P/E ratio 2022 555x
Yield 2022 -
Capitalization 1 244 M 1 244 M -
EV / Sales 2022 3,63x
EV / Sales 2023 4,05x
Nbr of Employees 511
Free-Float 82,5%
Chart CYTEK BIOSCIENCES, INC.
Duration : Period :
Cytek Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTEK BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 9,26 $
Average target price 11,67 $
Spread / Average Target 26,0%
EPS Revisions
Managers and Directors
Wen Bin Jiang President, Chief Executive Officer & Director
Patrik Sebastian Jeanmonod Chief Financial Officer
Ming Yan Director & Chief Technology Officer
Melik Ulusu VP-Operations & Integrated Supply Chain
Jack T. Ball Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CYTEK BIOSCIENCES, INC.-43.26%1 244
THERMO FISHER SCIENTIFIC-17.75%209 146
DANAHER CORPORATION-23.92%179 203
INTUITIVE SURGICAL, INC.-38.05%79 897
SIEMENS HEALTHINEERS AG-18.32%64 383
EDWARDS LIFESCIENCES CORPORATION-25.24%60 217